Eptifibatide

Eptifibatide Injection solution for injection must always be given as an intravenous bolus followed by the Eptifibatide Injection solution for infusion. 0 mcg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours.

If a patient undergoes PCI, Eptifibatide Injection infusion should be continued until hospital discharge or for up to 18-24 hours after the procedure, whichever comes first, allowing for 96 hours of therapy. 75 mg/mL injection) per hour.

0 mcg/kg/min. 75 mg/mL injection) per hour. 0 mcg/kg/min and a second 180 mcg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge or for up to 18-24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.

75 mg/mL injection) per hour. The recommended adult dose of eptifibatide in patients with moderate renal impairment (creatinine clearance of ≥30 -<50 mL/min, using the Cockcroft-Gault* equation), is an intravenous bolus of 180 mcg/kg administered immediately before the initiation of the procedure, followed by a second 180 mcg/kg bolus administered 10 minutes after the first bolus injection.

Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.

1).

1 Acute Coronary Syndrome (ACS) Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI).

2) ] .

Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin. Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.

1).